# Biomarkers for Apatinib and Bevacizumab in Second-line Therapy for Colorectal Cancer(BABST-C)

> **NCT03743428** · NA · SUSPENDED · sponsor: **Shenzhen People's Hospital** · enrollment: 40 (estimated)

## Conditions studied

- Colorectal Neoplasms

## Interventions

- **DRUG:** Apatinib Mesylate Tablets
- **DRUG:** Bevacizumab Injection

## Key facts

- **NCT ID:** NCT03743428
- **Lead sponsor:** Shenzhen People's Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2020-10-22
- **Primary completion:** 2025-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 40 (ESTIMATED)
- **Why stopped:** Too slow speed for recruiting.
- **Last updated:** 2023-06-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03743428

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03743428, "Biomarkers for Apatinib and Bevacizumab in Second-line Therapy for Colorectal Cancer(BABST-C)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03743428. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*